Cargando…

A Review of Eptinezumab Use in Migraine

We present a review of the efficacy and safety profile of eptinezumab (also known by the brand name Vyepti), a calcitonin gene-related peptide (CGRP) monoclonal antibody (mAb) developed by Lundbeck Seattle BioPharmaceuticals, Inc., that received its first approval in the USA on 21 February 2020 for...

Descripción completa

Detalles Bibliográficos
Autores principales: Datta, Abhigyan, Maryala, Shashi, John, Rebecca
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cureus 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8446121/
https://www.ncbi.nlm.nih.gov/pubmed/34540516
http://dx.doi.org/10.7759/cureus.18032

Ejemplares similares